Analytical Data
-
Gene name
GYPA/CD235a
- Application
-
Alternative Names
Glycophorin-A; GYPA; PAS-2; CD235a; GPA
-
Species
Mouse
-
Source
HEK293
-
Tag
N-hFc;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P14220
-
Expression Region
M1-V108
-
Protein Length
Extracellular Domain
-
Molecular Weight
60-66 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Glycophorin A (GYPA), also known as CD235a, is a sialoglycoprotein primarily expressed on the surface of human red blood cells. It plays a crucial role in maintaining the structural integrity of the erythrocyte membrane and contributes to the negative charge of the red blood cell surface, which is vital for preventing cell aggregation. Research on GYPA/CD235a has garnered significant interest due to its implications in blood transfusion medicine, genetic blood disorders, and its potential as a target for therapeutic interventions. Additionally, variations in GYPA can serve as important markers for ethnic blood group typing and have been linked to certain diseases, including malaria, where the binding of the parasite to GYPA can influence susceptibility. The recombinant production of GYPA/CD235a, therefore, provides a valuable tool for studying its biological function and interactions, as well as for developing diagnostic reagents and therapeutic strategies. Advances in recombinant technology enable the generation of GYPA in sufficient quantities and with proper post-translational modifications, facilitating detailed investigations into its roles and applications in clinical settings. Researchers are exploring various expression systems, including mammalian cells, to ensure proper glycosylation patterns that are essential for the protein's functionality. Overall, the study of GYPA/CD235a not only enhances our understanding of erythrocyte biology but also opens avenues for novel therapeutic approaches in hematology and transfusion practices.
